MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Bio-IT World
September 2006
John Russell
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. mark for My Articles similar articles
Bio-IT World
March 8, 2005
John Russell
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. mark for My Articles similar articles
Bio-IT World
February 2006
John Russell
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. mark for My Articles similar articles
Bio-IT World
November 12, 2002
Michael Goldman
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2012
Ron Cohen
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? mark for My Articles similar articles
Bio-IT World
December 15, 2003
Mark D. Uehling
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
Bio-IT World
April 2007
John Russell
Whatever Happened to the Critical Path? Science progresses at its own rate and medical science is necessarily more cautious than other branches. But it feels like the lack of money and mindshare are turning the FDA's Critical Path Initiative into just another umbrella project. mark for My Articles similar articles
Bio-IT World
August 13, 2003
John Rhodes
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2005
Jill Wechsler
Washington Report: Crawford Steps Up As FDA's new commissioner takes the reins, his key challenge is restoring trust in the agency. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
Jill Wechsler
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. mark for My Articles similar articles
Bio-IT World
August 13, 2003
Brian Reid
Remaking the FDA New commissioner is pushing for greater use of technology and innovation to speed the flow of drugs to market. mark for My Articles similar articles
Bio-IT World
April 2007
Malorye Allison
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
Jill Wechsler
Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead. mark for My Articles similar articles
BusinessWeek
October 18, 2004
Catherine Arnst
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma mark for My Articles similar articles
BusinessWeek
December 13, 2004
John Carey
How To Prevent Another Vioxx The tragedy should spur Congress and the FDA to improve the safety of new drugs. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2014
Jill Wechsler
Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D. mark for My Articles similar articles
The Motley Fool
April 4, 2007
Brian Lawler
Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas. mark for My Articles similar articles
The Motley Fool
December 31, 2011
Brian Orelli
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. mark for My Articles similar articles
The Motley Fool
August 17, 2007
Brian Orelli
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. mark for My Articles similar articles
The Motley Fool
September 25, 2008
Brian Lawler
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. mark for My Articles similar articles
Bio-IT World
June 17, 2004
John Russell
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. mark for My Articles similar articles
Bio-IT World
August 13, 2002
Mark D. Uehling
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? mark for My Articles similar articles
The Motley Fool
November 13, 2009
Brian Orelli
Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant. mark for My Articles similar articles
The Motley Fool
February 23, 2005
Stephen D. Simpson
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2009
Porth & Sillup
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. mark for My Articles similar articles
BusinessWeek
November 29, 2004
Catherine Arnst
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2006
Jill Wechsler
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. mark for My Articles similar articles
The Motley Fool
December 2, 2010
Brian Orelli
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. mark for My Articles similar articles
The Motley Fool
October 18, 2006
Brian Lawler
Another Hard Pill to Swallow A former FDA chief will take the fall for not disclosing holdings, but the pharmaceuticals industry needs more than that. mark for My Articles similar articles
The Motley Fool
June 2, 2009
Brian Orelli
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. mark for My Articles similar articles
The Motley Fool
October 9, 2008
Brian Orelli
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. mark for My Articles similar articles
Bio-IT World
November 19, 2004
Mark D. Uehling
Safety Last? Antiquated reporting of adverse events in clinical trials is costing pharma billions and forcing it to seek new pharmacovigilance solutions. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2011
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? mark for My Articles similar articles
The Motley Fool
February 10, 2005
Stephen D. Simpson
eResearch Regains Heartbeat Increased FDA and consumer worries about cardiac safety should continue to fuel the cardiac researcher's growth. mark for My Articles similar articles
Bio-IT World
Dec 2006/Jan 2007
John Russell
Setting the Systems Bio Syllabus An interview with David de Graaf about Pfizer's growing comfort with systems biology. mark for My Articles similar articles
The Motley Fool
February 22, 2005
Charly Travers
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. mark for My Articles similar articles
The Motley Fool
December 31, 2010
Brian Orelli
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Walter Armstrong
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. mark for My Articles similar articles
The Motley Fool
November 12, 2009
Brian Orelli
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Brad Miles
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. mark for My Articles similar articles
The Motley Fool
September 14, 2010
Luke Timmerman
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. mark for My Articles similar articles
HBS Working Knowledge
November 17, 2003
Martha Lagace
The Politics of Innovation Mark B. McClellan, the new commissioner of the Food and Drug Administration, described what the FDA is doing to bridge the gap between the high cost of innovation and patients' demand for lower prices. mark for My Articles similar articles
Bio-IT World
Dec 2006/Jan 2007
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. mark for My Articles similar articles